Brought to you by 
Gene therapy start-up Homology Medicines raises $43.5mm in Series A capital
14 Nov 2017
Executive Summary
Homology Medicines Inc. (gene therapy for rare diseases) raised $43.5mm in its Series A financing round. The preferred stock financing was led by 5AM Ventures and ARCH Venture Partners with participation from Temasek, Deerfield Management, and ARCH Overage Fund. The company also appointed its leadership and advisory board.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Gene Therapy, Cell Therapy
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Gene therapy start-up Homology Medicines raises $43.5mm in Series A capital
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice